SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
SUPERNUS PHARMACEUTICALS INC
(NQNM:SUPN Last Sale: 22.14 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (SUPN : $22.14)
$1,163,184 million Market Cap at Market Close, July 1, 2022
Biomedics SubIndustry up .00% / Health Industry up .00% Today
Research Report Earnings Snapshot - Last 11/11/18
Fact Sheet
Financial Statements
Peer Comparison
Annual Reports


Focused on central nervous system, or CNS, diseases. Goal is to be a leading specialty pharmaceutical company developing and commercializing new medicines in neurology and psychiatry. Have a track record of developing novel products by applying proprietary technologies to known drugs to improve existing therapies and to enable the treatment of new indications. Key proprietary technology platforms include: Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). IPO at $5 April 30, 2012. Raised $50 million, selling 10 million shares, 42% of the outstanding. Lead Manager: Citigroup.
Historical Charts    Technical Analysis
No Historical Data available for SUPN

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common SUPN $22.14 $22.14 0 .0 $21.91 $23.03 652,685 $21.91 $23.03 52,537,659
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10126
Common Stock #############

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex